Tags

Type your tag names separated by a space and hit enter

Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects.
Clin Pharmacol Ther. 2007 Jul; 82(1):63-9.CP

Abstract

After cannabis consumption there is only limited knowledge about the pharmacokinetic (PK) and metabolic properties of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC), which is formed by oxidative breakdown from Delta(9)-tetrahydrocannabinol (THC). Despite widely-varying concentrations observed in smoking studies, attempts have been made to interpret consumption behavior with special regard to a cumulated or decreasing concentration of CTHC in serum. Ten healthy nonsmoking white male individuals received 5 mg CTHC intravenously over 10 min. Highest serum concentrations of CTHC were observed at the end of the infusion (336.8+/-61.7 microg/l) followed by a quick decline. CTHC concentration could be quantified up to 96 h after administration, with a terminal elimination half-life of 17.6+/-5.5 h. Total clearance was low (91.2+/-24.0 ml/min), with renal clearance having only a minor contribution (0.136+/-0.094 ml/min). This first metabolite-based kinetic approach will allow an advanced understanding of CTHC PKs data obtained in previous studies with THC.

Authors+Show Affiliations

Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17410118

Citation

Glaz-Sandberg, A, et al. "Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) After Intravenous Administration of CTHC in Healthy Human Subjects." Clinical Pharmacology and Therapeutics, vol. 82, no. 1, 2007, pp. 63-9.
Glaz-Sandberg A, Dietz L, Nguyen H, et al. Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clin Pharmacol Ther. 2007;82(1):63-9.
Glaz-Sandberg, A., Dietz, L., Nguyen, H., Oberwittler, H., Aderjan, R., & Mikus, G. (2007). Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clinical Pharmacology and Therapeutics, 82(1), 63-9.
Glaz-Sandberg A, et al. Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) After Intravenous Administration of CTHC in Healthy Human Subjects. Clin Pharmacol Ther. 2007;82(1):63-9. PubMed PMID: 17410118.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. AU - Glaz-Sandberg,A, AU - Dietz,L, AU - Nguyen,H, AU - Oberwittler,H, AU - Aderjan,Rolf, AU - Mikus,Gerd, Y1 - 2007/04/04/ PY - 2007/4/6/pubmed PY - 2007/8/19/medline PY - 2007/4/6/entrez SP - 63 EP - 9 JF - Clinical pharmacology and therapeutics JO - Clin Pharmacol Ther VL - 82 IS - 1 N2 - After cannabis consumption there is only limited knowledge about the pharmacokinetic (PK) and metabolic properties of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC), which is formed by oxidative breakdown from Delta(9)-tetrahydrocannabinol (THC). Despite widely-varying concentrations observed in smoking studies, attempts have been made to interpret consumption behavior with special regard to a cumulated or decreasing concentration of CTHC in serum. Ten healthy nonsmoking white male individuals received 5 mg CTHC intravenously over 10 min. Highest serum concentrations of CTHC were observed at the end of the infusion (336.8+/-61.7 microg/l) followed by a quick decline. CTHC concentration could be quantified up to 96 h after administration, with a terminal elimination half-life of 17.6+/-5.5 h. Total clearance was low (91.2+/-24.0 ml/min), with renal clearance having only a minor contribution (0.136+/-0.094 ml/min). This first metabolite-based kinetic approach will allow an advanced understanding of CTHC PKs data obtained in previous studies with THC. SN - 0009-9236 UR - https://www.unboundmedicine.com/medline/citation/17410118/Pharmacokinetics_of_11_nor_9_carboxy_Delta_9__tetrahydrocannabinol__CTHC__after_intravenous_administration_of_CTHC_in_healthy_human_subjects_ L2 - https://doi.org/10.1038/sj.clpt.6100199 DB - PRIME DP - Unbound Medicine ER -